Anson Funds Management’s Neurogene NGNE Stock Holding History

Anson Funds Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,970	Closed	-$474K	–	40
2018 Q4	$474K	Buy	+10,970	New	+$534K	0.28%	21

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Anson Funds Management's NGNE Position: Q1 2019 in Review

Anson Funds Management sold out of Neurogene (NGNE) in Q1 2019, closing a stake of 10,970 shares — an estimated $474K sold.

Anson Funds Management first reported a position in NGNE in Q4 2018 and held it in 1 quarter. The position peaked at $474K in Q4 2018. 34 funds tracked by Wall St. Rank hold NGNE as of Q1 2019.

Anson Funds Management reported no remaining Neurogene position as of Q1 2019 after selling out during the quarter.
Anson Funds Management sold 10,970 Neurogene shares in Q1 2019, an estimated $474K.
Anson Funds Management first reported a position in Neurogene in Q4 2018 and held it in 1 quarter.
Anson Funds Management's Neurogene position peaked at $474K in Q4 2018.
34 funds tracked by Wall St. Rank held Neurogene as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.